NASDAQ:STML - Stemline Therapeutics Stock Price, Forecast & News

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

Stemline Therapeutics Inc (NASDAQ:STML) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.42) by $0.08. The biopharmaceutical company had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million. View Stemline Therapeutics' Earnings History.

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Stemline Therapeutics.

Stemline Therapeutics issued an update on its FY 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $43.2-43.2 million, compared to the consensus revenue estimate of $46.44 million.

7 Wall Street analysts have issued 1 year price targets for Stemline Therapeutics' stock. Their forecasts range from $14.00 to $33.00. On average, they anticipate Stemline Therapeutics' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 270.1% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.

News coverage about STML stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Stemline Therapeutics.

Some companies that are related to Stemline Therapeutics include Zogenix (ZGNX), Amneal Pharmaceuticals (AMRX), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Phibro Animal Health (PAHC), I-Mab (ARQT), Revance Therapeutics (RVNC), Dermira (DERM), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Akebia Therapeutics (AKBA), Portola Pharmaceuticals (PTLA) and Athenex (ATNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Exelixis (EXEL), Viking Therapeutics (VKTX), ZIOPHARM Oncology (ZIOP), Gilead Sciences (GILD), Fate Therapeutics (FATE), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Karyopharm Therapeutics (KPTI) and Opko Health (OPK).

Stemline Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (4.69%), State Street Corp (4.31%), Alliancebernstein L.P. (3.76%), Goldman Sachs Group Inc. (2.70%), Sectoral Asset Management Inc (2.04%) and FMR LLC (1.76%). Company insiders that own Stemline Therapeutics stock include Alan S Forman, David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View Institutional Ownership Trends for Stemline Therapeutics.

STML stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, UBS Group AG, Citigroup Inc., Rafferty Asset Management LLC, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund and Cubist Systematic Strategies LLC. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View Insider Buying and Selling for Stemline Therapeutics.

STML stock was purchased by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Alliancebernstein L.P., Rhenman & Partners Asset Management AB, FMR LLC, State Street Corp, Bullseye Asset Management LLC, Empire Life Investments Inc. and Farallon Capital Management LLC. View Insider Buying and Selling for Stemline Therapeutics.

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STML stock can currently be purchased for approximately $5.81.

Stemline Therapeutics has a market capitalization of $291.26 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.View Additional Information About Stemline Therapeutics.

The official website for Stemline Therapeutics is http://www.stemline.com/.

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]